Development of an in vivo‐relevant drug product performance method for an amorphous solid dispersion

[1]  H. Fadda,et al.  Leveraging BCS in Development: A Case Study. , 2015, Molecular pharmaceutics.

[2]  M. Khan,et al.  Chemometric Model Development and Comparison of Raman and (13)C Solid-State Nuclear Magnetic Resonance-Chemometric Methods for Quantification of Crystalline/Amorphous Warfarin Sodium Fraction in the Formulations. , 2015, Journal of pharmaceutical sciences.

[3]  M. Khan,et al.  Comparison of X-ray powder diffraction and solid-state nuclear magnetic resonance in estimating crystalline fraction of tacrolimus in sustained-release amorphous solid dispersion and development of discriminating dissolution method. , 2015, Journal of pharmaceutical sciences.

[4]  C. Subrahmanyam,et al.  Development and Validation of Discriminating and Biorelevant Dissolution Test for Lornoxicam Tablets , 2015, Indian journal of pharmaceutical sciences.

[5]  G. Bredael,et al.  A Strategy for Quality Control Dissolution Method Development for Immediate-Release Solid Oral Dosage Forms , 2015 .

[6]  A. Thombre,et al.  In vitro and in vivo characterization of amorphous, nanocrystalline, and crystalline ziprasidone formulations. , 2012, International journal of pharmaceutics.

[7]  J. Tao,et al.  Solution Behavior of PVP-VA and HPMC-AS-Based Amorphous Solid Dispersions and Their Bioavailability Implications , 2012, Pharmaceutical Research.

[8]  Leonardo M. B. Ferreira,et al.  A discriminating dissolution method for glimepiride polymorphs. , 2012, Journal of pharmaceutical sciences.

[9]  A. Paudel,et al.  Influence of Solvent Composition on the Miscibility and Physical Stability of Naproxen/PVP K 25 Solid Dispersions Prepared by Cosolvent Spray-Drying , 2011, Pharmaceutical Research.

[10]  Anette Müllertz,et al.  Lipid-based Formulations for Danazol Containing a Digestible Surfactant, Labrafil M2125CS: In Vivo Bioavailability and Dynamic In Vitro Lipolysis , 2008, Pharmaceutical Research.

[11]  S. Stegemann,et al.  When poor solubility becomes an issue: from early stage to proof of concept. , 2007, European journal of pharmaceutical sciences : official journal of the European Federation for Pharmaceutical Sciences.

[12]  Anant Paradkar,et al.  Stabilization and Improved in Vivo Performance of Amorphous Etoricoxib using Gelucire 50/13 , 2005, Pharmaceutical Research.

[13]  Christian Leuner,et al.  Characterization of Solid Dispersions of Itraconazole and Hydroxypropylmethylcellulose Prepared by Melt Extrusion, Part II , 2003, Pharmaceutical Research.

[14]  J. Crison,et al.  A Theoretical Basis for a Biopharmaceutic Drug Classification: The Correlation of in Vitro Drug Product Dissolution and in Vivo Bioavailability , 1995, Pharmaceutical Research.

[15]  Lieven Baert,et al.  Characterization of solid dispersions of itraconazole and hydroxypropylmethylcellulose prepared by melt extrusion--Part I. , 2003, International journal of pharmaceutics.

[16]  Samuel H. Yalkowsky,et al.  Solubility and Solubilization in Aqueous Media , 1999 .

[17]  A. Serajuddin,et al.  Solid dispersion of poorly water-soluble drugs: early promises, subsequent problems, and recent breakthroughs. , 1999, Journal of pharmaceutical sciences.

[18]  A. Rajabi-Siahboomi,et al.  Influence of drug:hydroxypropylmethylcellulose ratio, drug and polymer particle size and compression force on the release of diclofenac sodium from HPMC tablets. , 1999, Journal of controlled release : official journal of the Controlled Release Society.

[19]  G. Levy.  EFFECT OF CERTAIN TABLET FORMULATION FACTORS ON DISSOLUTION RATE OF THE ACTIVE INGREDIENT. I. IMPORTANCE OF USING APPROPRIATE AGITATION INTENSITIES FOR IN VITRO DISSOLUTION RATE MEASUREMENTS TO REFLECT IN VIVO CONDITIONS. , 1963, Journal of pharmaceutical sciences.